Spyre Therapeutics, Inc. — All Filings
744 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-K/A
10-Q
10-Q/A
144
3
3/A
4
4/A
424B3
424B4
424B5
5
8-A12B
8-K
8-K/A
ARS
CERTNAS
CORRESP
CT ORDER
D
DEF 14A
DEFA14A
DRS
EFFECT
FWP
POS AM
PRE 14A
PRER14A
S-1
S-1/A
S-3
S-3/A
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| SCHEDULE 13G | — | 0001214659-25-006773 | May 1, 2025 | — |
| DEF 14A | DEF 14A | 0001636282-25-000038 | Apr 14, 2025 | May 29, 2025 |
| DEFA14A | DEFA14A | 0001636282-25-000039 | Apr 14, 2025 | — |
| ARS | ARS | 0001636282-25-000040 | Apr 14, 2025 | Dec 31, 2024 |
| EFFECT | — | 9999999995-25-000659 | Mar 13, 2025 | — |
| POS AM | POS AM | 0001628280-25-011345 | Mar 7, 2025 | — |
| EFFECT | — | 9999999995-25-000613 | Mar 7, 2025 | — |
| 8-K | 8-K | 0001193125-25-048423 | Mar 6, 2025 | Feb 28, 2025 |
| CORRESP | — | 0001628280-25-010520 | Mar 5, 2025 | — |
| UPLOAD | — | 0000000000-25-002409 | Mar 4, 2025 | — |
| 10-K | 10-K | 0001636282-25-000020 | Feb 27, 2025 | Dec 31, 2024 |
| 8-K | 8-K | 0001636282-25-000022 | Feb 27, 2025 | — |
| S-8 | S-8 | 0001636282-25-000024 | Feb 27, 2025 | — |
| S-3 | S-3 | 0001628280-25-008686 | Feb 27, 2025 | — |
| SCHEDULE 13G/A | — | 0000950170-25-021223 | Feb 14, 2025 | — |
| SCHEDULE 13G/A | — | 0001415889-25-004231 | Feb 14, 2025 | — |
| SCHEDULE 13G/A | — | 0000950170-25-020484 | Feb 14, 2025 | — |
| 4 | FORM 4 | 0001636282-25-000009 | Jan 17, 2025 | Jan 15, 2025 |
| 4 | FORM 4 | 0001636282-25-000010 | Jan 17, 2025 | Jan 15, 2025 |
| 4 | FORM 4 | 0001636282-25-000007 | Jan 17, 2025 | Jan 15, 2025 |
| 4 | FORM 4 | 0001636282-25-000008 | Jan 17, 2025 | Jan 15, 2025 |
| 4 | FORM 4 | 0001636282-25-000002 | Jan 14, 2025 | Jan 10, 2025 |
| 8-K | 8-K | 0001193125-25-005015 | Jan 13, 2025 | — |
| 424B5 | 424B3 | 0001628280-24-048482 | Nov 19, 2024 | — |
| 8-K | 8-K | 0001628280-24-048527 | Nov 19, 2024 | Nov 18, 2024 |
| 424B5 | 424B5 | 0001628280-24-048293 | Nov 18, 2024 | — |
| 8-K | 8-K | 0001636282-24-000105 | Nov 18, 2024 | — |
| 10-Q/A | 10-Q/A | 0001636282-24-000113 | Nov 18, 2024 | Sep 30, 2024 |
| 10-K/A | 10-K | 0001636282-24-000107 | Nov 18, 2024 | Dec 31, 2023 |
| 10-Q/A | 10-Q/A | 0001636282-24-000109 | Nov 18, 2024 | Mar 31, 2024 |
| 10-Q/A | 10-Q/A | 0001636282-24-000111 | Nov 18, 2024 | Jun 30, 2024 |
| SC 13G/A | SC 13G/A | 0001104659-24-119333 | Nov 14, 2024 | — |
| SC 13G/A | SPYRE THERAPEUTICS, INC. | 0000902664-24-006526 | Nov 14, 2024 | — |
| SC 13G/A | — | 0001172661-24-004773 | Nov 14, 2024 | — |
| SC 13G/A | — | 0001493152-24-045810 | Nov 14, 2024 | — |
| SC 13G/A | SC 13G/A | 0001193125-24-258682 | Nov 14, 2024 | — |
| 8-K | 8-K | 0001628280-24-046860 | Nov 12, 2024 | — |
| SC 13G/A | — | 0000315066-24-002912 | Nov 12, 2024 | — |
| SC 13G | — | 0002012383-24-003588 | Nov 8, 2024 | — |
| 4 | FORM 4 | 0001636282-24-000089 | Nov 8, 2024 | Nov 6, 2024 |
| 10-Q | 10-Q | 0001636282-24-000083 | Nov 7, 2024 | Sep 30, 2024 |
| 8-K | 8-K | 0001636282-24-000085 | Nov 7, 2024 | — |
| S-8 | S-8 | 0001636282-24-000087 | Nov 7, 2024 | — |
| 4 | FORM 4 | 0001636282-24-000070 | Oct 28, 2024 | Oct 25, 2024 |
| 144 | — | 0001950047-24-007878 | Oct 25, 2024 | — |
| SC 13G | SCHEDULE 13G | 0001683168-24-007319 | Oct 23, 2024 | — |
| SC 13G | — | 0002012383-24-001245 | Oct 22, 2024 | — |
| 8-K | 8-K | 0001193125-24-237150 | Oct 15, 2024 | Oct 11, 2024 |
| EFFECT | — | 9999999995-24-003068 | Oct 2, 2024 | — |
| 3 | FORM 3 | 0001636282-24-000066 | Oct 1, 2024 | — |